A Phase Ib, Open-label Study of Safety and Pharmacokinetics of Volitinib in Combination With Docetaxel in Patients With Advanced Gastric Cancer
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2016
At a glance
- Drugs Docetaxel (Primary) ; Savolitinib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in advanced gastric adenocarcinoma with second-line MET gene amplified patients during Q4 2014 and for Second-line MET overexpression patients during 4 2014.
- 08 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.